Mancini A, Guitelman A, Levalle O, Aparicio N, Aszenmil G
J Androl. 1984 Jul-Aug;5(4):294-6. doi: 10.1002/j.1939-4640.1984.tb00791.x.
This study evaluated bromocriptine treatment in nine patients with prolactin secreting adenomas who continued to have elevated circulating levels of prolactin after surgery, and who were interested in improving their sperm counts. These patients were brought into the study 3.2 +/- 1.8 years (mean +/- SD) after surgery. All of them presented with high circulating levels of prolactin, and eight of the patients had oligozoospermia (range 0-10 X 10(6) spermatozoa/ml). LH and testosterone levels were low in seven patients, and eight patients had low FSH values. All patients were treated for 90 days with 7.5 mg/day of bromocriptine. After treatment, prolactin levels decreased significantly in all patients, while sperm counts increased significantly in five of them. Testosterone levels increased in four subjects. Bromocriptine therefore seems useful in the management of this type of patient because of the observed decline in prolactin levels and the increase in sperm counts. Possible mechanisms involved in this action are discussed.
本研究评估了溴隐亭对9例催乳素分泌性腺瘤患者的治疗效果。这些患者术后循环催乳素水平持续升高,且希望提高精子计数。这些患者在术后3.2±1.8年(均值±标准差)被纳入研究。他们均表现为循环催乳素水平升高,其中8例患者患有少精子症(范围为0 - 10×10⁶精子/ml)。7例患者促黄体生成素(LH)和睾酮水平较低,8例患者促卵泡生成素(FSH)值较低。所有患者均接受每日7.5mg溴隐亭治疗90天。治疗后,所有患者的催乳素水平均显著下降,其中5例患者的精子计数显著增加。4例患者的睾酮水平升高。因此,鉴于观察到的催乳素水平下降和精子计数增加,溴隐亭似乎对这类患者的治疗有用。本文还讨论了这一作用可能涉及的机制。